Author:
Bobrova N. M.,Romanovskaya T. V.
Reference76 articles.
1. Allan, J.M., Smith, A.G., Wheatley, K., et al., Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy, Blood, 2004, vol. 104, no. 13, pp. 3872–3877.
2. Auberger, P. and Puissant, A., Autophagy, a key mechanism of oncogenesis and resistance in leukemia, Blood, 2017, vol. 129, no. 5, pp. 547–552.
3. Bertuccio, S.N., Serravalle, S., Astolfi, A., et al., Identification of a cytogenetic and molecular subgroup of acute myeloid leukemias showing sensitivity to L-asparaginase, Oncotarget, 2017, vol. 8, no. 66, pp. 109915–109923.
4. Blokhin, D.Yu., The reasons for the limited efficiency of anticancer therapy in terms of cell biology, Ross. Bioter. Zh., 2005, vol. 4, no. 3, pp. 18–23.
5. Bosman, M.C.J., Schuringa, J.J., and Vellenga, E., Constitutive NF-κB activation in AML: causes and treatment strategies, Crit. Rev. Oncol. Hematol., 2016, vol. 98, pp. 35–44. https://doi.org/10.1016/j.critrevonc.2015.10.001